Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Oncology/Epidemiology
  • Published:

Clinical Oncology/Epidemiology

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group

British Journal of Cancer volume 74, pages 961–963 (1996)Cite this article

Abstract

The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with < 4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

  1. University of Antwerp, Belgium

    J van Meerbeeck

Authors
  1. J van Meerbeeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Debruyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N van Zandwijk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. PE Postmus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. MC Pennucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F van Breukelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Galdermans
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Groen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P Pinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M van Glabbeke
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E van Marck
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G Giaccone
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Meerbeeck, J., Debruyne, C., van Zandwijk, N. et al. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 74, 961–963 (1996). https://doi.org/10.1038/bjc.1996.465

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1996.465

This article is cited by

Search

Advanced search

Quick links